This page provides a list of some of the company’s key events in the near future. An Investor Relations calendar can be found here.

Upcoming events

Date
Event
11.12.2019
Lymfactin poster presentation at SABCS (San Antonio Breast Cancer Symposium®), San Antonio, TX, USA
13.01 - 16.01.2020
37th Annual J.P. Morgan Healthcare Conference, San Fransisco, CA, USA
06.02.2020
Swiss Nordic BIO 2020, Zurich, Switzerland
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
11.11.2019
FN
04.11.2019
PR
26.09.2019
FN
02.09.2019
PR
28.08.2019
ER
01.07.2019
PR
31.05.2019
FN
31.05.2019
FN
31.05.2019
FN
31.05.2019
FN
31.05.2019
FN
31.05.2019
FN
31.05.2019
FN
28.05.2019
FN
06.05.2019
FN
23.04.2019
FN
11.04.2019
FN
28.03.2019
FN
22.03.2019
FN
20.03.2019
FN
15.03.2019
FN
13.03.2019
FN
13.03.2019
FN
13.03.2019
FN
12.03.2019
FN
12.03.2019
FN
12.03.2019
FN
28.02.2019
ER
15.02.2019
FN
15.02.2019
FN
Public materials related to our company and products will be presented on this page. Presentations in Finnish language can be found here. Please note that these presentations are provided for historical use only. Herantis will not keep these presentations up-to-date after their actual presenting date.
World Bioethics Day is a good day to learn about bioethics

Did you know that Bioethics is a very broad and challenging branch of science with potentially significant impact on our future?

How to invest smartly in biotech?

The big difference in biotech investments compared to more established businesses is that you need to assess a possible future success rather than consider existing cash flow and profit.

Artificially intelligent drug development

Artificial intelligence (AI) will shape our world in the coming years. People already speculate how AI can superhumanly solve any human problem. What will its role be in healthcare?

The price of life (and drugs)

Developing of novel drugs is always a high-risk endeavor and success should result in a financial reward. However, what is an acceptable cost for the treatment of severe rare disorders?

How big is big: The economic burden of disease

The global direct healthcare costs are approaching $10 trillion. What does that signify? The CEO gives a concrete example to elucidate the potential significance of our work.

Big Pharma and risk acceptance for true innovation

The development of new drugs is always risky. The more innovative an approach is the higher are the risks. For a real breakthrough in an unmet clinical need, high risk acceptance is needed.

A different view to Parkinson’s disease

Seppo Nieminen, a Parkinson's patient active in the regional Parkinson's group of Keski-Uusimaa in Finland, gives his thoughts on the current publishing practice on news in Parkinson's.